Development of RNA aptamers for therapeutics

Bibliographic Information

Other Title
  • バイオ素材による創薬とDDS  RNAアプタマーを用いた分子標的医薬の開発
  • RNAアプタマーを用いた分子標的医薬の開発
  • RNA アプタマー オ モチイタ ブンシ ヒョウテキ イヤク ノ カイハツ

Search this article

Description

In recent years, RNA aptamers have been regarded as the next generation of antibody therapeutic drugs. RNA aptamers are selected by in vitro selection referred to as SELEX and after going through truncation and modification, they become candidates for therapeutic drugs. PEGylation is used for substantial improvement of pharmacokinetics. An aptamer itself is potentially a therapeutic drug, but it can also be used as a drug delivery agent by conjugating it with an agent such as an anti-cancer agent. In this review, developmental processes and typical properties of aptamer therapeutic drugs will be reviewed. vWF aptamer, which is now in phase II clinical studies, and MK aptamer, which is being developed by RIBOMIC Inc., will be also reviewed.

Journal

  • Drug Delivery System

    Drug Delivery System 23 (5), 534-543, 2008

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

Citations (2)*help

See more

References(43)*help

See more

Details 詳細情報について

Report a problem

Back to top